Takeda’s Uloric treatment receives approval

Takeda’s Ulroic (TMX-67, febuxostat) has received approval.

Jointly developed with Teijin Pharma, the once-daily oral drug is used for the treatment of hyperuricemia in patients who have gout.

The therapy – available in 40 mg and 80 mg doses – lowers the level of uric acid in the blood and has been approved following tests analysing its safety and efficacy.

President of Teijin Pharma Osamu Nishikawa said the endorsement follows the green light from the European Medicines Agency for Ipsen.

Yasuchika Hasegawa, president of Takeda, added the approval offers “a novel treatment option for patients who have hyperuricemia with gout, where there are still unmet clinical needs”.

Takeda noted the drug is not recommended for treatment of asymptomatic hyperuricemia.

Founded in 1781 and incorporated in 1925, Takeda has UK research and development facilities located in London and Cambridge.

In addition, the organisation has production facilities in countries including Italy and Ireland.